Giampaolo Talamo, MD
Medical Oncology · Washington, DCNPI 1073540332
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,287 of the $1,929 with a category attached, or 66.7%. 19 manufacturers reported payments, led by Bristol Myers Squibb at 24.7% of the total. Reporting peaked in 2019 at $683 and has fallen 73.5% since, to $181 in 2025.
Across 30 payments — averaging $64.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$476
- Incyte Corporation$288
- Amgen$225
- AstraZeneca$187
- Exelixis Inc.$150
- Seagen Inc.$125
- plus $479 from 13 others
Across 1 payment — averaging $3392.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$3K
What the payments were for
- Speaking & faculty fees$47625%
- Food & beverage$1,28767%
- Education$1669%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 1 | $476 |
| Incyte Corporation | 3 | $288 |
| Amgen | 3 | $225 |
| AstraZeneca | 3 | $187 |
| Exelixis Inc. | 2 | $150 |
| Seagen Inc. | 1 | $125 |
| Astellas Pharma US Inc | 1 | $88 |
| Bayer | 2 | $62 |
| Novocure Inc. | 1 | $61 |
| Genentech USA, Inc. | 3 | $49 |
| Lilly USA, LLC | 2 | $43 |
| Daiichi Sankyo Inc. | 1 | $37 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Puma Biotechnology, Inc. | 1 | $24 |
| Sobi, Inc | 1 | $20 |
| Tempus AI, Inc | 1 | $18 |
| Merck | 1 | $17 |
| AbbVie | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,929 in reported general payments places this provider in the 55th percentile of 29 medical oncology providers in District of Columbia.
See all medical oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 15 | $226,077 |
| Dexamethasone | 21 | $449 |
| Prochlorperazine Maleate | 18 | $367 |
| Anastrozole | 23 | $291 |
| Oxycodone Hcl | 11 | $264 |
| Prednisone | 24 | $76 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Washington
- Nancy DawsonWashington$1.7M
- Joshua ReussWashington$218K
- Pashna MunshiWashington$189K
- Michael PishvaianWashington$147K
- Kieron DunleavyWashington$139K
- Asim AminWashington$120K
- Mitchell SmithWashington$41K
- Channing PallerWashington$33K
- Solmaz SahebjamWashington$31K
- Khaled El-ShamiWashington$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.